Emergent BioSolutions (EBS) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.65 -3.04%
EPS Growth %: -31.3%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
SFNC, CSBR, MAN, More
EPS Growth %: -31.3%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
SFNC, CSBR, MAN, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $101.5 million versus the consensus estimate of $111.2 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ManpowerGroup (MAN) Tops Q2 EPS by 4c; offers guidance
- Benchmark Reiterates Buy Rating on Equity Bancshares (EQBK)
- State Street (STT) Tops Q2 EPS by 33c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
